Cargando…

Treatment Refractoriness in Chronic Lymphocytic Leukemia: Old and New Molecular Biomarkers

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Despite its indolent clinical course, therapy refractoriness and disease progression still represent an unmet clinical need. Before the advent of pathway inhibitors, chemoimmunotherapy (CIT) was the commonest option for CLL tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maher, Nawar, Mouhssine, Samir, Matti, Bassam Francis, Alwan, Alaa Fadhil, Gaidano, Gianluca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299596/ https://www.ncbi.nlm.nih.gov/pubmed/37373521 http://dx.doi.org/10.3390/ijms241210374

Ejemplares similares

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
por: Matti, Bassam Francis, et al.
Publicado: (2013)

Richter Syndrome: From Molecular Pathogenesis to Druggable Targets
por: Mouhssine, Samir, et al.
Publicado: (2022)

Druggable Molecular Pathways in Chronic Lymphocytic Leukemia
por: Almasri, Mohammad, et al.
Publicado: (2022)

Immunological Aspects of Richter Syndrome: From Immune Dysfunction to Immunotherapy
por: Mahmoud, Abdurraouf Mokhtar, et al.
Publicado: (2023)

The Spectrum of Genetic Defects in Chronic Lymphocytic Leukemia
por: Rossi, Davide, et al.
Publicado: (2012)

Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Alwan, Alaa Fadhil, et al.
Publicado: (2020)

A step ahead toward precision medicine for chronic lymphocytic leukemia
por: Patriarca, Andrea, et al.
Publicado: (2020)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
por: Alqasim, Alauldeen Mudhafar Zubair, et al.
Publicado: (2018)

New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Gallazzi, Marco, et al.
Publicado: (2022)

Precision Medicine Management of Chronic Lymphocytic Leukemia
por: Moia, Riccardo, et al.
Publicado: (2020)

Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

The clinical implications of gene mutations in chronic lymphocytic leukaemia
por: Rossi, Davide, et al.
Publicado: (2016)

Refractory chronic lymphocytic leukemia – new therapeutic strategies
por: Schnaiter, Andrea, et al.
Publicado: (2010)

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
por: Shustik, C., et al.
Publicado: (2017)

Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia
por: Wang, Jiguang, et al.
Publicado: (2014)

In vitro study of the effect of resveratrol purified from the skin of Iraqi black grape (Vitis vinifera) on lymphocyte cultures isolated from the blood of patients with lymphoma
por: Hasan, Zainab Yaseen Mohammed, et al.
Publicado: (2022)

MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia
por: Ferracin, Manuela, et al.
Publicado: (2010)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia with Chromothripsis in an Old Woman
por: Tan, Li, et al.
Publicado: (2015)

Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014)

Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
por: Rigolin, Gian Matteo, et al.
Publicado: (2021)

What Are the Attributes Prioritized in the Choice of Therapy in Chronic Lymphocytic Leukemia? A Patient-physician Cross-matching Analysis of a Discrete Choice Experiment
por: Laurenti, Luca, et al.
Publicado: (2022)

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic
por: Rossi, Davide, et al.
Publicado: (2020)

Diffuse pulmonary infiltrates in an old man with chronic lymphocytic leukemia
por: Hosseinnezhad, Alireza, et al.
Publicado: (2011)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukemia
por: Eyre, Toby A., et al.
Publicado: (2020)

The immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy
por: Arruga, Francesca, et al.
Publicado: (2023)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

Developing Molecular Signatures for Chronic Lymphocytic Leukemia
por: Cornet, Edouard, et al.
Publicado: (2015)

Management of a 75-Year-Old Lady with Refractory Chronic Myelogenous Leukemia
por: Sobash, Philip T., et al.
Publicado: (2020)

Atypical Chronic Myeloid Leukemia: Where Are We Now?
por: Crisà, Elena, et al.
Publicado: (2020)

Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
por: Porrazzo, Marika, et al.
Publicado: (2020)

Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia
por: Castro, J E, et al.
Publicado: (2014)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Coutre, Steven E., et al.
Publicado: (2018)

Phase II study of acalabrutinib in ibrutinibintolerant patients with relapsed/refractory chronic lymphocytic leukemia
por: Rogers, Kerry A., et al.
Publicado: (2021)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome
por: Barbanti, Maria Chiara, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_efq4qop5f11mj4k5utddah0lvc